You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm has a molecular SARS-CoV-2 test in development on its Revogene platform and will be distributing an antigen test.
The test is designed to save resources by testing for the four viruses in one test using single nasopharyngeal, oropharyngeal, or nasal swab samples.
The company recently received FDA Emergency Use Authorization for its SARS-CoV-2 PCR test while its data-driven COVID-19 research initiative is moving along.
Centogene will provide its oropharyngeal swabs and conduct RT-PCR testing, while U-Diagnostics will collect samples and report the results.
Qiagen has benefited from unexpected tailwinds due to COVID-19 testing and envisions post-pandemic growth with recently acquired NeuMoDx as a key contributor.
The firm noted that this is the first EUA for saline oral rinse collection used for SARS-CoV-2 testing, adding to its other approved collection methods.
The company's Eonis assay, which leverages RT-PCR technology, can be used to simultaneously tests for SMA, SCID, and XLA in newborns.
The PCR assay is used for the detection of SARS-CoV-2 RNA in anterior nasal swab specimens self-collected at home using the Vo' COVID-19 Test Home Collection Kit.
The firm said being able to test asymptomatic people with its Panther Fusion SARS-CoV-2 assay could play an important role in reopening the economy.
The test runs on multiple GeneXpert systems and tests nasopharyngeal and nasal swabs or nasal wash/aspirate specimens.
NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.
According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.
In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.
Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.